These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25644128)

  • 21. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
    Panomvana D; Sripradit S; Angthararak S
    J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Achieving treat to target in gout: a clinical practice improvement project.
    Lim AY; Shen L; Tan CH; Lateef A; Lau TC; Teng GG
    Scand J Rheumatol; 2012; 41(6):450-7. PubMed ID: 22839705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urate-lowering therapy for gout: focus on febuxostat.
    Love BL; Barrons R; Veverka A; Snider KM
    Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inpatient management of gout in a New Zealand hospital: a retrospective audit.
    Kennedy NJ; Healy PJ; Harrison AA
    Int J Rheum Dis; 2016 Feb; 19(2):205-10. PubMed ID: 25873399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study.
    Liu C; Zhao Q; Zhen Y; Gao Y; Tian L; Wang L; Ji L; Liu G; Ji Z; Liu K
    Can J Cardiol; 2013 Sep; 29(9):1048-54. PubMed ID: 23395281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population.
    Robinson PC; Taylor WJ; Dalbeth N
    J Rheumatol; 2015 Sep; 42(9):1702-7. PubMed ID: 26233513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. More allopurinol is needed to get gout patients < 0.36 mmol/l: a gout audit in the form of a before-after trial.
    Arroll B; Bennett M; Dalbeth N; Hettiarachchi D; Ben C; Shelling G
    J Prim Health Care; 2009 Dec; 1(4):315-8. PubMed ID: 20690341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study.
    Coburn BW; Cheetham TC; Rashid N; Chang JM; Levy GD; Kerimian A; Low KJ; Redden DT; Bridges SL; Saag KG; Curtis JR; Mikuls TR
    Contemp Clin Trials; 2016 Sep; 50():106-15. PubMed ID: 27449546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An audit of a therapeutic drug monitoring service for allopurinol therapy.
    Kannangara DR; Ramasamy SN; Ray JE; Jones G; Graham GG; Williams KM; Day RO
    Ther Drug Monit; 2013 Dec; 35(6):863-6. PubMed ID: 24263644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Febuxostat: a new treatment for hyperuricaemia in gout.
    Edwards NL
    Rheumatology (Oxford); 2009 May; 48 Suppl 2():ii15-ii19. PubMed ID: 19447778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opportunities for improving medication use and monitoring in gout.
    Singh JA; Hodges JS; Asch SM
    Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uric acid, allopurinol therapy, and mortality in patients with acute heart failure--results of the Acute HEart FAilure Database registry.
    Málek F; Ošťádal P; Pařenica J; Jarkovský J; Vítovec J; Widimský P; Linhart A; Fedorco M; Coufal Z; Miklík R; Krűger A; Vondraková D; Špinar J
    J Crit Care; 2012 Dec; 27(6):737.e11-24. PubMed ID: 22699032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Casebook consults: improving outcomes in gout (multimedia activity).
    Doghramji PP; Mandell BF; Pope RS
    Am J Med; 2012 Aug; 125(8):S1. PubMed ID: 22840678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Febuxostat in the management of gout: a cost-effectiveness analysis.
    Smolen LJ; Gahn JC; Mitri G; Shiozawa A
    J Med Econ; 2016; 19(3):265-76. PubMed ID: 26535593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality use of allopurinol in the elderly.
    Smith P; Karlson N; Nair BR
    J Qual Clin Pract; 2000 Mar; 20(1):42-3. PubMed ID: 10821456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
    Stevenson M; Pandor A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study.
    Richette P; Brière C; Hoenen-Clavert V; Loeuille D; Bardin T
    J Rheumatol; 2007 Oct; 34(10):2093-8. PubMed ID: 17896799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors associated with recurrent hospital admissions for gout: a case-control study.
    Hutton I; Gamble G; Gow P; Dalbeth N
    J Clin Rheumatol; 2009 Sep; 15(6):271-4. PubMed ID: 19734730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.